Eli Lilly and Company have announced that ixekizumab (Taltz) has been recommended by NICE for use as a treatment option within the NHS in England, Wales and Northern Ireland for adults with severe plaque psoriasis who have responded inadequately to standard systemic therapies.
The announcement follows on from NICE’s final Technology Appraisal Guidance (TAG) on the use of ixekizumab, which was published today.
The Scottish Medicines Consortium published its guidance on the use of ixekizumab by the NHS in Scotland earlier this month. It is accepted for restricted use within NHS Scotland to treat moderate to severe plaque psoriasis in patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Ixekizumab is licensed for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy. It is designed to specifically designed to target IL-17A, a protein which plays a key role in plaque psoriasis.
The NICE appraisal was supported by data on ixekizumab from three randomised double-blinded Phase III clinical trials in more than 3,800 patients across 21 countries.